Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $20.57

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been given a consensus rating of “Moderate Buy” by the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $20.57.

Several research firms have commented on STOK. TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 26th. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Friday, June 28th. Wedbush reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of Stoke Therapeutics in a report on Thursday, July 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. Finally, Canaccord Genuity Group cut their price target on Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, May 7th.

Stoke Therapeutics Trading Down 0.4 %

Stoke Therapeutics stock opened at $13.58 on Monday. The business’s 50 day simple moving average is $14.38 and its 200 day simple moving average is $10.32. Stoke Therapeutics has a 12 month low of $3.35 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, May 6th. The company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.03. The firm had revenue of $4.22 million for the quarter, compared to analysts’ expectations of $3.33 million. Sell-side analysts expect that Stoke Therapeutics will post -2.3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $13.75, for a total value of $137,500.00. Following the completion of the transaction, the insider now directly owns 2,485 shares of the company’s stock, valued at approximately $34,168.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 11.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Redmile Group LLC grew its position in Stoke Therapeutics by 93.2% in the first quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock worth $68,486,000 after acquiring an additional 2,447,543 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Stoke Therapeutics during the 2nd quarter valued at about $19,835,000. Baker BROS. Advisors LP lifted its position in Stoke Therapeutics by 65.9% in the 1st quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock worth $45,474,000 after buying an additional 1,338,309 shares during the last quarter. Lynx1 Capital Management LP boosted its stake in Stoke Therapeutics by 25.0% in the first quarter. Lynx1 Capital Management LP now owns 3,696,820 shares of the company’s stock worth $49,907,000 after buying an additional 739,902 shares in the last quarter. Finally, Artal Group S.A. bought a new position in Stoke Therapeutics during the first quarter valued at approximately $4,050,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.